T1	HMM 24 41	erectile function
T2	HMM 46 76	health-related quality of life
T3	HMM 223 263	the effectiveness and cost-effectiveness
T4	HMM 279 334	on erectile function and health-related quality of life
T5	HMM 940 1013	outcome was erectile function (International Index of Erectile Function-5
T6	HMM 1041 1246	included male ED-specific quality of life (MED-QoL), quality-adjusted life years (QALYs) using the generic Euroqol measure (EQ-5D), endothelial function, cardiovascular risk, cholesterol and health service
T7	HMM 1287 1318	difference in erectile function
T8	HMM 1433 1447	improvement in
T9	HMM 1494 1500	0.04).
T10	HMM 1501 1561	Both 10-year cardiovascular risk and low-density lipoprotein
T11	HMM 1686 1717	change in endothelial function.
T12	HMM 1718 1752	The frequency of sexual encounters
T13	HMM 1756 1799	correlated with improved erectile function.
T14	HMM 1800 1849	The joint distribution of costs and QALY benefits
T15	HMM 1884 1916	simvastatin being cost-effective
T16	HMM 2180 2188	analysis
T17	HMM 2192 2206	costs and QALY
